CN102796705A - Dac hyp组合物和方法 - Google Patents

Dac hyp组合物和方法 Download PDF

Info

Publication number
CN102796705A
CN102796705A CN2012102472614A CN201210247261A CN102796705A CN 102796705 A CN102796705 A CN 102796705A CN 2012102472614 A CN2012102472614 A CN 2012102472614A CN 201210247261 A CN201210247261 A CN 201210247261A CN 102796705 A CN102796705 A CN 102796705A
Authority
CN
China
Prior art keywords
daclizumab
composition
dac hyp
dac
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012102472614A
Other languages
English (en)
Chinese (zh)
Inventor
T·哈特曼
P·W·索尔
J·E·伯基
M·C·韦森
P·Y·黄
T·J·罗宾逊
B·帕特里奇
J·Y·索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
Abbott Biomedical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biomedical filed Critical Abbott Biomedical
Priority to CN201710204584.8A priority Critical patent/CN107090040A/zh
Publication of CN102796705A publication Critical patent/CN102796705A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2012102472614A 2011-05-27 2012-05-25 Dac hyp组合物和方法 Pending CN102796705A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710204584.8A CN107090040A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490998P 2011-05-27 2011-05-27
US61/490,998 2011-05-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710204584.8A Division CN107090040A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法

Publications (1)

Publication Number Publication Date
CN102796705A true CN102796705A (zh) 2012-11-28

Family

ID=46177353

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710204584.8A Pending CN107090040A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法
CN2012102472614A Pending CN102796705A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710204584.8A Pending CN107090040A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法

Country Status (10)

Country Link
US (7) US20120301429A1 (enExample)
EP (1) EP2527429A3 (enExample)
JP (4) JP6055615B2 (enExample)
CN (2) CN107090040A (enExample)
AU (4) AU2012203095B2 (enExample)
BR (1) BR102012012673A8 (enExample)
CA (1) CA2777978A1 (enExample)
MX (1) MX339533B (enExample)
RU (2) RU2018119112A (enExample)
SG (1) SG185920A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102012012673A8 (pt) * 2011-05-27 2021-02-17 Abbott Biotherapeutics Corp célula ns0 modificada, métodos de produzir uma proteína recombinante, de obter uma célula hospedeira de mamífero, de sanitizar uma coluna de cromatografia com afinidade para proteína a e de tratar um paciente sofrendo de esclerose múltipla, vetor, composição, processos para colher uma proteína recombinante de uma cultura de célula e para produzir uma composição purificada de daclizumab, meios, e, tampão
WO2013022972A1 (en) 2011-08-08 2013-02-14 Abbott Biotherapeutics Corporation Methods of treating progressive forms of multiple sclerosis
CA2857298A1 (en) * 2011-11-30 2013-06-06 Abbvie Biotherapeutics Inc. Vectors and host cells comprising a modified sv40 promoter for protein expression
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US11014129B2 (en) 2013-09-04 2021-05-25 Emd Millipore Corporation Methods of cleaning a protein A based affinity chromatography column
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
EP3274359B1 (en) 2015-03-23 2022-11-02 Alexion Pharmaceuticals, Inc. Virus filtration
PT3334760T (pt) 2015-08-12 2021-04-23 Pfizer Cisteínas de anticorpos com cap e sem cap e utilizações das mesmas na conjugação de anticorpo-fármaco
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
WO2018027195A1 (en) * 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
KR20240152951A (ko) * 2017-01-30 2024-10-22 리제너론 파마슈티칼스 인코포레이티드 크로마토그래피에서 바이오버든을 감소시키기 위한 조성물 및 방법
EP3728288B1 (en) * 2017-12-21 2022-01-19 Genzyme Corporation Methods for enhanced removal of impurities during protein a chromatography
JP7739181B2 (ja) * 2019-04-17 2025-09-16 ブリストル－マイヤーズ スクイブ カンパニー クロマトグラフィー樹脂の再生方法
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
MX2022001166A (es) * 2019-08-01 2022-02-23 Regeneron Pharma Metodo para inactivacion viral.
MY190623A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
JP7631742B2 (ja) * 2020-11-10 2025-02-19 東ソー株式会社 ペプチド性リガンド固定化カラムの洗浄方法
MX2023012903A (es) * 2021-05-03 2023-11-08 Boehringer Ingelheim Int Metodo para producir spesolimab.
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276799A1 (en) * 2002-10-15 2005-12-15 Hinton Paul R Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430566A (en) * 1974-11-15 1976-03-31 Nestel Sa Isolation of proteins
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
RU2318537C2 (ru) * 2001-04-06 2008-03-10 Юниверсити Оф Бристоль Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
JP2005325133A (ja) * 2001-10-15 2005-11-24 Kirin Brewery Co Ltd 抗ｈｌａ−ｄｒ抗体の利用
US20040002135A1 (en) * 2002-03-28 2004-01-01 Sauer Paul W. Adapted NS0 cell lines with the ability to grow under glutamine-free conditions
EP1614693A4 (en) * 2003-03-31 2006-07-19 Kirin Brewery Purification of a human monoclonal antibody and human polyclonal antibody
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2007146847A2 (en) 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
JP2010510963A (ja) * 2006-06-14 2010-04-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー セラミックヒドロキシアパタイトを使用する抗体の精製方法
US20090209656A1 (en) * 2006-07-06 2009-08-20 Ge Healthcare Bio-Sciences Ab Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol
US20110003338A1 (en) * 2008-03-11 2011-01-06 Robert Bayer Antibodies with enhanced adcc function
US20100055098A1 (en) * 2008-08-28 2010-03-04 Facet Biotech Corporation Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2010138502A2 (en) * 2009-05-26 2010-12-02 Momenta Pharmaceuticals, Inc. Production of glycoproteins
AU2010256455A1 (en) 2009-06-05 2012-01-19 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
SG177577A1 (en) * 2009-08-07 2012-03-29 Emd Millipore Corp Methods for purifying a target protein from one or more impurities in a sample
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
IL323000A (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
BR102012012673A8 (pt) 2011-05-27 2021-02-17 Abbott Biotherapeutics Corp célula ns0 modificada, métodos de produzir uma proteína recombinante, de obter uma célula hospedeira de mamífero, de sanitizar uma coluna de cromatografia com afinidade para proteína a e de tratar um paciente sofrendo de esclerose múltipla, vetor, composição, processos para colher uma proteína recombinante de uma cultura de célula e para produzir uma composição purificada de daclizumab, meios, e, tampão

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276799A1 (en) * 2002-10-15 2005-12-15 Hinton Paul R Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JOHN E. BURKY ET AL.: "Protein-Free Fed-Batch Culture of Non-GS NS0 Cell Lines for Production of Recombinant Antibodies", 《BIOTECHNOLOGY AND BIOENGINEERING》, vol. 96, no. 2, 24 August 2006 (2006-08-24), XP009170623, DOI: 10.1002/bit.21060C *
KATSUHIRO MORI ET AL.: "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies", 《CYTOTECHNOLOGY》, 31 December 2007 (2007-12-31) *
S. Y. LIM, C. S. CONSTANTINESCU: "Current and future disease-modifying therapies in multiple sclerosis", 《J CLIN PRACT》, vol. 64, no. 5, 30 April 2010 (2010-04-30), XP009164316, DOI: 10.1111/j.1742-1241.2009.02261.x *
TAYMAR E. HARTMAN ET AL.: "Derivation and Characterization of Cholesterol-Independent Non-GS NS0 Cell Lines for Production of Recombinant Antibodies", 《BIOTECHNOLOGY AND BIOENGINEERING》, vol. 96, no. 2, 8 August 2006 (2006-08-08), XP009170624, DOI: 10.1002/bit.21099C *
YING ZHU ET AL.,: "NS0 Cell Damage by High Gas Velocity Sparging in Protein-Free and Cholesterol-Free Cultures", 《BIOTECHNOLOGY AND BIOENGINEERING》, vol. 101, no. 4, 24 April 2008 (2008-04-24), XP009170625, DOI: 10.1002/bit.21950 *
赵亮 等: "表达抗-CD25 单克隆抗体的GS-NS0 骨髓瘤细胞无血清培养及代谢特性", 《生物工程学报》, vol. 25, no. 7, 30 July 2009 (2009-07-30) *

Also Published As

Publication number Publication date
US20180127506A1 (en) 2018-05-10
US9340619B2 (en) 2016-05-17
RU2012121876A (ru) 2013-11-27
AU2016202873A1 (en) 2016-05-26
US20150274832A1 (en) 2015-10-01
RU2661764C2 (ru) 2018-07-19
EP2527429A2 (en) 2012-11-28
AU2012203095B2 (en) 2016-02-04
RU2018119112A (ru) 2018-11-07
US20120301429A1 (en) 2012-11-29
JP2018134091A (ja) 2018-08-30
US9260528B2 (en) 2016-02-16
MX339533B (es) 2016-05-30
MX2012006115A (es) 2012-12-04
US20200157230A1 (en) 2020-05-21
AU2018200654A1 (en) 2018-02-15
US20170247461A1 (en) 2017-08-31
SG185920A1 (en) 2012-12-28
AU2016202873B2 (en) 2018-02-22
AU2020202298A1 (en) 2020-04-23
AU2012203095A1 (en) 2012-12-13
US9815903B2 (en) 2017-11-14
JP6055615B2 (ja) 2016-12-27
BR102012012673A8 (pt) 2021-02-17
CA2777978A1 (en) 2012-11-27
JP2016210796A (ja) 2016-12-15
JP2020078348A (ja) 2020-05-28
US9676860B2 (en) 2017-06-13
BR102012012673A2 (pt) 2015-11-17
US20150197573A1 (en) 2015-07-16
CN107090040A (zh) 2017-08-25
US20150203583A1 (en) 2015-07-23
EP2527429A3 (en) 2013-10-30
JP2012244993A (ja) 2012-12-13

Similar Documents

Publication Publication Date Title
JP6055615B2 (ja) Ｄａｃｈｙｐ組成物および方法
US20180127507A1 (en) Methods of treating progressive forms of multiple sclerosis
EP3374399A1 (en) Composition and methods for anti-tnfr2 antibodies
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
US20240425596A1 (en) Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
EP4562048A1 (en) Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof
CN101460522A (zh) 糖基化抗体
CN119365214A (zh) 使用抗tigit抗体治疗淋巴瘤的方法
HK1178205A (en) Dac hyp compositions and methods
EP4562049A1 (en) Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and rhuph20 or variants or fragments thereof
HK40034257A (en) Anti-claudin 18.2 antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American California

Applicant after: Abbvie Biotherapeutics Inc.

Address before: American California

Applicant before: Abbott Biotherapeutics Corp.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ABBOTT BIOTHERAPEUTICS CORP. TO: ABBVIE BIOTHERAPEUTICS INC.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1178205

Country of ref document: HK

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE BIOTECHNOLOGY LTD.

Free format text: FORMER OWNER: ABBVIE BIOTHERAPEUTICS INC.

Effective date: 20150724

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150724

Address after: Bermuda Hamilton

Applicant after: Abbott Biotechnology Ltd.

Address before: American California

Applicant before: Abbvie Biotherapeutics Inc.

RJ01 Rejection of invention patent application after publication

Application publication date: 20121128

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1178205

Country of ref document: HK